Sirolimus (marketed as Rapamune)
This is a discussion on Sirolimus (marketed as Rapamune) within the FDA News forum, part of the Industry News and Updates category; The FDA is notifying healthcare professionals of clinical trial data that suggest increased mortality in stable liver transplant patients after ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
06-11-2009, 11:33 AM
|
|||
|
|||
Sirolimus (marketed as Rapamune)
The FDA is notifying healthcare professionals of clinical trial data that suggest increased mortality in stable liver transplant patients after conversion from a calcineurin inhibitor (CNI)-based immunosuppressive regimen to sirolimus (Rapamune).
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Efalizumab (marketed as Raptiva) Information | industry_news | FDA News | 0 | 04-08-2009 11:55 PM |
| FDA issues an Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix) | industry_news | FDA News | 0 | 01-26-2009 01:09 PM |
| FDA issues an Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Re | industry_news | FDA News | 0 | 06-07-2008 07:30 PM |
| FDA approves new Medication Guide and Label for Varenicline (marketed as Chantix) | industry_news | FDA News | 0 | 05-19-2008 03:47 PM |
© 2008 DrugManagementForum™ powered by |
 |